Last updated: September 7, 2026
Mavacamten, marketed by Bristol Myers Squibb as Camzyos, is the first FDA-approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy. Its commercial outlook is supported by a large underdiagnosed patient population, durable clinical differentiation and expansion into nonobstructive disease. Uptake is constrained by a boxed warning, mandatory REMS monitoring, echocardiography requirements, restricted distribution and competition from emerging cardiac myosin inhibitors.
Bristol Myers Squibb acquired mavacamten through its approximately $13.1 billion acquisition of MyoKardia in 2020. Camzyos generated a small initial contribution after its May 2022 U.S. launch, followed by accelerating sales as cardiologists gained experience with the product and the company expanded access through the CAMZYOS Risk Evaluation and Mitigation Strategy, or REMS.[1]
What is mavacamten and how does Camzyos work?
Mavacamten is an allosteric inhibitor of cardiac myosin ATPase activity. It reduces excessive actin-myosin cross-bridge formation, lowering hypercontractility and left ventricular outflow tract obstruction in hypertrophic cardiomyopathy.
The FDA approved Camzyos in April 2022 for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.[2]
| Product attribute |
Camzyos |
| Active ingredient |
Mavacamten |
| Manufacturer |
Bristol Myers Squibb |
| Original developer |
MyoKardia |
| U.S. approval |
April 2022 |
| Initial indication |
Adults with symptomatic NYHA class II-III obstructive HCM |
| Administration |
Once-daily oral capsule |
| U.S. regulatory control |
Boxed warning and CAMZYOS REMS |
| Therapeutic class |
Cardiac myosin inhibitor |
| Principal competitors |
Aficamten, traditional HCM medicines, septal reduction procedures |
Mavacamten has a long effective half-life, which supports once-daily dosing but increases the consequences of drug interactions, excessive exposure and left ventricular systolic dysfunction. The drug is contraindicated during pregnancy because fetal harm may occur.
How large is the mavacamten and hypertrophic cardiomyopathy market?
The addressable market is materially larger than current Camzyos sales. HCM affects approximately one in 500 people, although diagnosis rates remain below the estimated disease prevalence.[3] Obstructive HCM represents a substantial proportion of diagnosed cases, and many patients remain symptomatic despite beta blockers, calcium-channel blockers or disopyramide.
The commercial opportunity has several layers:
- Newly diagnosed obstructive HCM patients.
- Patients with persistent symptoms despite conventional therapy.
- Patients who are poor candidates for or unwilling to undergo septal reduction therapy.
- Patients treated at high-volume HCM centers.
- Potential expansion into nonobstructive HCM.
- International patients reached through future regulatory approvals.
The principal market constraint is patient management rather than disease prevalence. Camzyos requires serial echocardiographic assessment of left ventricular ejection fraction and careful management of cytochrome P450 drug interactions. The REMS requires certified prescribers and pharmacies, patient enrollment and ongoing monitoring.[4]
What were Camzyos sales and Bristol Myers Squibb’s financial trajectory?
Camzyos sales followed a typical specialty-launch pattern: limited revenue during the launch year, acceleration as treatment centers became operational, and increasing contribution from repeat prescriptions.
| Period |
Financial trajectory |
| 2020 |
Bristol Myers Squibb acquired MyoKardia for approximately $13.1 billion, primarily to obtain mavacamten.[5] |
| 2022 |
U.S. launch began after FDA approval. Revenue was limited by a new REMS infrastructure and gradual center activation. |
| 2023 |
Sales increased as more cardiology practices prescribed the product and patient onboarding improved. |
| 2024 onward |
Revenue growth depended on U.S. penetration, refill persistence, international expansion and additional indications. |
Bristol Myers Squibb has not disclosed Camzyos as a standalone segment with the same detail as its largest products in every reporting period. The company reports product sales within its cardiovascular portfolio and provides launch commentary in annual and quarterly filings.[1]
The acquisition economics depend on whether mavacamten becomes a multibillion-dollar product before patent and competitive pressure intensify. The original transaction price reflected the potential for a first-in-class therapy in a large chronic disease category, not the product’s early post-launch revenue.
What factors could accelerate Camzyos revenue?
Revenue growth can accelerate through:
- Higher diagnosis of obstructive HCM.
- Greater cardiologist familiarity with the drug.
- Increased use before septal reduction procedures.
- Broader prescribing outside specialized HCM centers.
- Better REMS workflow and faster patient enrollment.
- Approval in nonobstructive HCM.
- Additional international approvals.
- Increased persistence among patients who respond clinically.
What factors could reduce the financial trajectory?
The main risks are:
- Slow patient onboarding caused by REMS requirements.
- Treatment discontinuation caused by monitoring burden.
- Drug interactions and temporary treatment interruptions.
- Payer restrictions and prior authorization.
- Physician preference for established therapies.
- Aficamten competition.
- Safety-related regulatory action.
- Failure to demonstrate sufficient benefit in nonobstructive HCM.
- Patent challenges or earlier-than-expected generic entry.
What patents protect mavacamten and Camzyos?
Mavacamten is protected by a combination of compound, pharmaceutical composition, treatment-method, dosing and formulation rights. The practical exclusivity position is broader than a single chemical patent because commercial protection may depend on several patent families and the scope of FDA-listed patents.
The relevant protection categories include:
| Protection category |
Commercial purpose |
| Compound patents |
Protect mavacamten and structurally related compounds |
| Composition patents |
Cover pharmaceutical preparations containing mavacamten |
| Method-of-use patents |
Cover treatment of obstructive HCM and related cardiac conditions |
| Dosing patents |
Cover titration, monitoring and dose-adjustment regimens |
| Formulation patents |
Protect capsule composition, stability and manufacturing characteristics |
| Regulatory exclusivity |
Delay certain FDA approvals independently of patent claims |
The FDA Orange Book is the controlling public source for patents listed against the approved Camzyos product. Patent listings can change through owner submissions, FDA review and court outcomes. The commercial assessment should distinguish between expiration of a core compound patent and the expiration of later method, dosing or formulation patents.[6]
Public patent records associated with mavacamten have included U.S. patent families assigned to MyoKardia and later held by Bristol Myers Squibb. The estate is strongest where claims cover the active compound or a commercially necessary treatment regimen. Method-of-use patents are generally more vulnerable than composition-of-matter claims because generic applicants can attempt a non-infringing label or challenge the relevance of the claimed indication.
When does mavacamten lose exclusivity?
Camzyos exclusivity is layered:
- FDA five-year new chemical entity exclusivity began with the April 2022 approval and generally prevented submission of an ANDA relying on the product’s approval for five years, subject to statutory exceptions.
- Patent protection may extend beyond regulatory exclusivity.
- Orange Book-listed patents can trigger a 30-month stay if challenged through a properly served Paragraph IV notice and litigation is filed within the statutory period.
- Pediatric exclusivity, if granted, could add six months to qualifying protections.
- Patent-term adjustment or patent-term extension could alter individual patent dates.
The earliest practical generic-entry date cannot be determined solely from the approval date. It depends on the live Orange Book list, patent claims, any Paragraph IV certifications, litigation, settlements and the proposed generic label.
As a small-molecule product, Camzyos is exposed to conventional generic competition rather than biosimilar competition. No biosimilar pathway applies to mavacamten. A generic applicant would normally use an abbreviated new drug application, demonstrate pharmaceutical equivalence and bioequivalence, and address listed patents through Paragraph IV, Paragraph III or a section viii statement.
What is the Orange Book status of Camzyos?
Camzyos is an FDA-approved small-molecule prescription drug and is eligible for Orange Book patent listing. The relevant listed patents may cover the drug substance, product formulation, methods of use and dosing regimens.
The Orange Book analysis should answer four questions:
- Which patents are currently listed?
- What are the expiration dates after patent-term adjustments?
- Which claims cover the approved label?
- Would a generic applicant need a full-label, partial-label or non-infringing carve-out strategy?
A patent with a later expiration date does not automatically prevent generic entry if the generic applicant successfully invalidates it, designs around it or carves out the relevant indication. Conversely, a method-of-use patent can remain commercially meaningful if the protected indication is central to prescribing and the generic label cannot realistically omit it.
Which companies are challenging mavacamten?
As of the available public record through 2024, the most important competitive threat was not a launched generic but Cytokinetics’ aficamten program.
Aficamten compared with mavacamten
| Factor |
Mavacamten |
Aficamten |
| Developer |
MyoKardia, now Bristol Myers Squibb |
Cytokinetics |
| Mechanism |
Cardiac myosin inhibitor |
Cardiac myosin inhibitor |
| Commercial status |
FDA-approved and marketed |
Clinical-stage through 2024 |
| Main target |
Obstructive HCM |
Obstructive and potentially nonobstructive HCM |
| Differentiation issue |
First-mover status and clinical experience |
Potentially shorter half-life and simpler titration |
| Key commercial hurdle |
REMS and monitoring burden |
Regulatory approval and clinical adoption |
Aficamten’s potential advantage is pharmacokinetic control. A shorter half-life could permit faster dose adjustment and recovery if systolic function declines. That could reduce physician concern about prolonged exposure and potentially simplify patient management. Camzyos retains first-mover advantages, established clinical evidence, treatment-center familiarity and an installed patient base.
Traditional HCM therapies remain relevant. Beta blockers, verapamil, diltiazem and disopyramide are inexpensive and familiar. Surgical myectomy and alcohol septal ablation remain established options for selected patients with substantial obstruction. These alternatives limit the proportion of all HCM patients who will receive a cardiac myosin inhibitor.
What generic entry risks exist for Camzyos?
Generic entry risk is moderate over the medium term and potentially high after the strongest patent barriers expire.
Near-term risk
Near-term risk is limited by:
- Regulatory exclusivity.
- A complex REMS.
- Narrow specialist prescribing.
- Product-specific monitoring requirements.
- Potentially dense patent coverage.
- The difficulty of establishing a commercially workable generic distribution model.
Long-term risk
Long-term risk increases when:
- The core compound patent expires.
- ANDA applicants can obtain approval with a manageable monitoring system.
- Payers mandate substitution.
- Multiple generic manufacturers enter simultaneously.
- Prescribers become comfortable using a generic product.
- The treatment label becomes standardized across products.
Generic erosion could be slower than for a conventional primary-care medicine because Camzyos requires specialist oversight and ongoing echocardiography. It could also be faster than expected if several manufacturers launch at risk or settle with the patent holder for an agreed entry date.
How strong is the mavacamten patent estate?
The estate is commercially meaningful but not invulnerable.
Strengths
- First-mover product with a well-defined indication.
- Multiple potential patent categories.
- FDA-approved use tied to a specific clinical population.
- Technical manufacturing and formulation know-how.
- Regulatory complexity that raises generic commercialization costs.
- Bristol Myers Squibb’s litigation and market-access resources.
Weaknesses
- Method-of-use claims can face validity and non-infringement challenges.
- Dosing claims may be vulnerable if the generic label uses alternative titration language.
- A small-molecule product is ultimately exposed to ANDA competition.
- Long-term sales depend on one principal product rather than a diversified cardiovascular franchise.
- An improved cardiac myosin inhibitor could reduce the value of later patent protection.
What manufacturing and intellectual-property barriers affect mavacamten?
Mavacamten manufacturing requires control of active pharmaceutical ingredient purity, impurity profiles, solid-state properties, capsule quality and stability. Those requirements can create technical barriers, but they do not provide the same long-term protection as a valid composition patent.
The most commercially relevant manufacturing barriers are:
- Consistent API production at commercial scale.
- Control of impurities and degradation products.
- Stability across the approved shelf life.
- Reproducible capsule content uniformity.
- Compliance with current good manufacturing practices.
- Validation of any generic formulation used with the required monitoring program.
Manufacturing know-how may delay competitors but generally does not prevent them from developing an equivalent process.
What litigation and settlement issues affect Camzyos?
The principal legal questions are likely to involve:
- Paragraph IV certifications against Orange Book-listed patents.
- Whether method-of-use patents cover the full proposed generic label.
- Whether dosing and monitoring claims are infringed.
- Patent validity under obviousness, written description and enablement standards.
- The scope of any settlement restricting generic entry.
- Antitrust scrutiny of delayed-entry agreements.
No major public generic litigation outcome had established an earlier Camzyos entry date through 2024. That status can change quickly after an ANDA applicant sends a Paragraph IV notice. A filed patent case would normally provide the clearest signal on the timing of potential generic competition.
What is the FDA regulatory status of mavacamten?
Camzyos has full FDA approval for symptomatic obstructive HCM in adults with NYHA class II-III disease. Its regulatory profile is unusually restrictive for a chronic oral therapy because of the risk of heart failure from excessive reduction in systolic function.
Key FDA controls include:
- Boxed warning for heart failure risk.
- Baseline and follow-up echocardiograms.
- Contraindication in patients with symptomatic heart failure or LVEF below the specified threshold.
- Contraindication during pregnancy.
- Drug-interaction restrictions.
- Mandatory CAMZYOS REMS enrollment and monitoring.[2][4]
The regulatory pathway for nonobstructive HCM would require separate clinical evidence. Success could materially expand the treated population, but the benefit-risk profile may be more difficult to establish because obstruction is absent and the clinical rationale differs.
How does mavacamten compare with aficamten and conventional HCM therapy?
Camzyos has the strongest current commercial position because it is approved and has clinical adoption. Aficamten may compete through ease of titration, shorter exposure and potentially lower monitoring friction. Conventional treatments compete primarily on price, familiarity and availability.
| Dimension |
Camzyos |
Aficamten |
Conventional therapy |
| Approval status through 2024 |
Approved |
Development-stage |
Established |
| Mechanism |
Cardiac myosin inhibition |
Cardiac myosin inhibition |
Hemodynamic symptom control |
| Price potential |
Specialty-drug pricing |
Likely specialty pricing |
Mostly generic |
| Monitoring burden |
High |
Potentially lower |
Generally lower |
| Disease modification potential |
Reduces hypercontractility and obstruction |
Similar intended role |
Symptom-focused |
| Patent exposure |
Small-molecule patent risk |
Future patent estate |
Mature generic competition |
What is the likely Camzyos launch scenario?
The most likely commercial scenario is continued growth followed by a slower expansion curve as the company reaches more of the diagnosed obstructive HCM population.
Base case
Camzyos becomes the established first-line cardiac myosin inhibitor for appropriately selected symptomatic obstructive HCM patients. Sales grow through deeper penetration of HCM centers and broader cardiology adoption, then moderate as aficamten approaches approval and payers negotiate.
Upside case
Nonobstructive HCM approval, international expansion, improved REMS execution and strong treatment persistence create a substantially larger revenue base. In this case, the product could become a major cardiovascular franchise before loss of exclusivity.
Downside case
REMS burden, payer controls, adverse safety signals, weak nonobstructive data or aficamten differentiation limit adoption. Camzyos remains a meaningful specialty product but fails to justify the acquisition price through organic sales alone.
Key Takeaways
- Mavacamten is the first approved cardiac myosin inhibitor and is marketed in the U.S. as Camzyos.
- Bristol Myers Squibb acquired MyoKardia for approximately $13.1 billion to obtain the drug and its development platform.
- The commercial opportunity is large because HCM is prevalent, underdiagnosed and undertreated.
- Revenue growth is constrained by REMS enrollment, echocardiographic monitoring, drug interactions and specialist prescribing.
- Camzyos is a small molecule, so its long-term competition will come from generics rather than biosimilars.
- The patent estate likely combines compound, composition, dosing and method-of-use protection, with the Orange Book determining the relevant listed barriers.
- Aficamten is the most important branded competitive threat through 2024.
- The value of Camzyos depends on expansion beyond obstructive HCM, international approvals, treatment persistence and the timing of generic entry.
- The principal legal risk is a future Paragraph IV challenge followed by litigation over method-of-use, dosing or formulation patents.
- Camzyos has a credible path to becoming a major specialty cardiovascular product, but the $13.1 billion acquisition requires sustained growth and protection from rapid competitive substitution.
FAQs
Is mavacamten the same as Camzyos?
Yes. Mavacamten is the active ingredient, and Camzyos is Bristol Myers Squibb’s U.S. brand name.
Is Camzyos a biologic or a small-molecule drug?
Camzyos is a small-molecule oral drug. Future competitors would generally pursue an ANDA, not a biosimilar application.
Can Camzyos be used for nonobstructive hypertrophic cardiomyopathy?
The initial FDA approval covers symptomatic obstructive HCM. Use in nonobstructive HCM requires separate regulatory support and is not automatically covered by the original approval.
Why does Camzyos require echocardiograms?
Mavacamten can reduce cardiac contractility excessively and increase the risk of heart failure. Echocardiography is used to monitor left ventricular ejection fraction and guide dose interruption or adjustment.
What is the biggest commercial threat to Camzyos?
The largest branded threat is aficamten, while the largest long-term pricing threat is generic mavacamten after applicable regulatory and patent protections expire.
References
- Bristol Myers Squibb. (2024). 2023 annual report. Bristol Myers Squibb Company.
- U.S. Food and Drug Administration. (2022). Camzyos prescribing information.
- Ommen, S. R., Mital, S., Burke, M. A., Day, S. M., Deswal, A., Elliott, P., Evanovich, L. L., Hung, J., Hurst, R. T., Kittleson, M.,Link, M. S., Maron, M. S., Martinez, M. W., McKenna, W. J., Raman, S. V., and American Heart Association. (2020). 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation, 142(25), e558-e631.
- U.S. Food and Drug Administration. (2022). CAMZYOS Risk Evaluation and Mitigation Strategy.
- Bristol Myers Squibb. (2020). Bristol Myers Squibb to acquire MyoKardia for $13.1 billion.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
